Effect of ridogrel, a combined thromboxane A2 synthase inhibitor/prostaglandin endoperoxide receptor antagonist, on the lysis of platelet rich coronary arterial thrombi with recombinant tissue-plasminogen activator in a canine model - Collen, D; Masuda, M; Lu, HR (Fibrinolysis, 1992)